Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Open access
Liu, Xiaoyan, Li, Zhe, Liu, Shuai, Sun, Jing, Chen, Zhanghua, Jiang, Min, Zhang, Qingling, Wei, Yinghua, Wang, Xin, Huang, Yi-You, Shi, Yinyi, Xu, Yanhui, Xian, Huifang, Bai, Fan, Ou, Changxing, Xiong, Bei, Lew, Andrew M., Cui, Jun, Fang, Rongli, Huang, Hui, Zhao, Jincun, Hong, Xuechuan, Zhang, Yuxia, Zhou, Fuling, Luo, Hai-Bin · 2020 · Acta Pharmaceutica Sinica B

Abstract

The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro . It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2020.04.008

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 274

Metadata

Authors
Liu, X., Li, Z., Liu, S., Sun, J., Chen, Z., Jiang, M., Zhang, Q., Wei, Y., Wang, X., Huang, Y.-Y., Shi, Y., Xu, Y., Xian, H., Bai, F., Ou, C., Xiong, B., Lew, A. M., Cui, J., Fang, R., Huang, H., Zhao, J., Hong, X., Zhang, Y., Zhou, F., & Luo, H.-B.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2020-07
Volume
10
Issue
7
Pages
1205-1215
ISSN
2211-3835 (ISSN-L)
OpenAlex
W3016961971
Cited by
274
References
44
FWCI
7.42
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. https://app.cochat.ai/papers/10.1016/j.apsb.2020.04.008
The paper
Liu, X., Li, Z., Liu, S., Sun, J., Chen, Z., Jiang, M., Zhang, Q., Wei, Y., Wang, X., Huang, Y.-Y., Shi, Y., Xu, Y., Xian, H., Bai, F., Ou, C., Xiong, B., Lew, A. M., Cui, J., Fang, R., . . . Luo, H.-B. (2020). Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2020.04.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.